scholarly journals Immune Thrombocytopenic Purpura in Patients with COVID-19

2020 ◽  
Author(s):  
Sabine Revuz ◽  
Nathalie Vernier ◽  
Leilah Saadi ◽  
Julien Campagne ◽  
Sophie Poussing ◽  
...  
Keyword(s):  
Immune Thrombocytopenic Purpura ◽  
Immune Thrombocytopenia ◽  
Intravenous Immunoglobulins ◽  
Immune Mechanism ◽  
Thrombocytopenic Purpura ◽  
Common Causes

We described three COVID-19-infected patients with profound immune thrombocytopenia causing haemorrhagic mucocutaneous complications. We conclude that an immune mechanism was responsible as common causes were excluded. Since corticoids were considered harmful in the circumstances, the patients were successfully treated with intravenous immunoglobulins without later relapse.

scholarly journals Immune Thrombocytopenia as a Consequence of Rocky Mountain Spotted Fever

2017 ◽  
Vol 10 (3) ◽  
pp. 945-947 ◽  
Author(s):  
Cherisse Baldeo ◽  
Karan Seegobin ◽  
Lara Zuberi
Keyword(s):  
Idiopathic Thrombocytopenic Purpura ◽  
Immune Thrombocytopenic Purpura ◽  
Immune Thrombocytopenia ◽  
Spotted Fever ◽  
Rocky Mountain ◽  
Rocky Mountain Spotted Fever ◽  
Thrombocytopenic Purpura ◽  
Common Causes ◽  
Primary Immune Thrombocytopenia ◽  
Tick Borne Disease

Primary immune thrombocytopenia (ITP) – also called idiopathic thrombocytopenic purpura or immune thrombocytopenic purpura – is an acquired thrombocytopenia caused by autoantibodies against platelet antigens. It is one of the more common causes of thrombocytopenia in otherwise asymptomatic adults. Rocky Mountain spotted fever (RMSF) is a potentially lethal, but curable, tick-borne disease. We present a case of ITP that was triggered by RMSF.

scholarly journals Knee Joint Tuberculosis Presenting as Immune Thrombocytopenia

1970 ◽  
Vol 10 (1) ◽  
pp. 28-30
Author(s):  
Mohammad Abdullah Az Zubayer Khan ◽  
Fazle Rabbi Mohammed ◽  
Md Ziaus Shams ◽  
Shaymal Sarker ◽  
Md Billal Alam
Keyword(s):  
Public Health ◽  
Knee Joint ◽  
Immune Thrombocytopenia ◽  
Case Reports ◽  
Rare Event ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Immune Mechanism ◽  
Thrombocytopenic Purpura ◽  
Case Documentation

Tuberculosis (TB) is a major public health problem of increasing proportions in Bangladesh for last several decades. A total of 350,641 cases were reported in Bangladesh in 2006 representing an incidence of 225 per 100,000 population for that year. Many hematological derangements such as anaemia, leukocytosis or pancytopenia can occur in association with TB. However isolated thrombocytopenia is rare and most commonly occur via a non immune mechanism in the setting of pancytopenia that develop secondary to granulomatous infiltration of the bone marrow.  However immune thrombocytopenic purpura (ITP) in a patient with TB is exceedingly a rare event. Here we report a case of ITP associated with TB of knee joint in whom thrombocytopenia and TB were successfully treated. A casual association between joint TB and ITP is extraordinarily rare and to our knowledge this is the first such case documentation in Bangladesh, although a few case reports citing association of TB and ITP are found in literature.   doi:10.3329/jom.v10i1.2001 J Medicine 2009; 10: 28-30

Incidence of Primary Immune Thrombocytopenia (ITP) in Adults in One Region of Russia

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4941-4941
Author(s):  
Anait L. Melikyan ◽  
Elena I Pustovaya ◽  
Elena M. Volodicheva ◽  
Tamara I Kolosheinova ◽  
Marina V Kalinina ◽  
...  
Keyword(s):  
Incidence Rate ◽  
Immune Thrombocytopenic Purpura ◽  
Immune Thrombocytopenia ◽  
Response To Therapy ◽  
Research Database ◽  
Newly Diagnosed ◽  
Thrombocytopenic Purpura ◽  
Target Region ◽  
Primary Immune Thrombocytopenia ◽  
Epidemiological Characteristics

Abstract Introduction. Primary immune thrombocytopenia is a rare disease1. The incidence of ITP is not well estimated in Russia and worldwide. In adults it varies from 1,6 to 3,9/100 000 person-years2-3. The gender and age-associated results are discussed and differ in several investigations4-6. Study objectives: evaluation of the incidence of primary immune thrombocytopenia in adults in one region of Russia Patients and methods. The data source is the Registry of the patients with primary ITP in Russia. 272 adult patients: 77 males (28%) and 195 females (72%), age from 16 to 89 years (median 44 years) with ITP (ICD-10 code D69.3), newly diagnosed cases during the period from 12 Jan 2014 to 24 May 2016. Results. 221 (81%) cases were newly diagnosed in 12 regions of Russia in which registration was performed most actively - more than 5 cases for the duration of the study. But only one region was selected for the first evaluation of epidemiological characteristics because of the number of reasons. There is one hematological central clinic in this region in which diagnosis of ITP can be verified and patients with ITP are treated and monitored most properly. The early started and fully performed registration process can be regarded as covered most part of region population in this target region. 86 cases (27 male, 59 female) were registered in the target region. The gender-age distribution was following: male: age <41 = 10 (37%), age <41-60 = 7 (26%), age >60 = 10 (37%); female: age <29 = 10 (49%), age <41-60 = 15 (25%), age >60 = 15 (25%). The estimated incidence rate in the target region is shown in table 1. The estimated incidence rates in gender-age strata in the target region are demonstrated in table 2. Conclusion. Overall ITP incidence in one region of Russia is 3.20/100 000 person-years. It is compatible to the incidence in other European countries. Our data demonstrate the rise of incidence rate in males with age and its decrease with age in female population. Literature. 1) Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from international working group. Blood. 2009; 113(11): 2386--93. doi: 10.1182/blood-2008-07-162503. 2) Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010; 85(3): 174-180. 3) Moulis G, Palmaro A, Montastruc J-L, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a natiowide population-based study in France. Blood. 2014; 124(22): 3308-3315. 4) Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4: 2377-83 5) Schoonen WM, Kucera G, Coelson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practise Research Database. Br J Haematol 2009; 145(2): 235-244. 6) Lisukov I.A., Maschan A.A., Shamardina A.V., Chagorova T.V., Davydkin I.L., Sycheva T.M., et al. Immune thrombocytopenia: clinical manifestations and response to therapy. Intermediate analysis of data of the Russian register of patients with primary immune thrombocytopenia and review of literature. Oncogematologiya. 2013; 2: 61--9]. Disclosures No relevant conflicts of interest to declare.

scholarly journals Severe immune thrombocytopenic purpura in critical COVID-19: a case report

2020 ◽  
Author(s):  
Valérie Lévesque ◽  
Émilie Milaire ◽  
Daniel Corsilli ◽  
Benjamin Rioux-Massé ◽  
François Martin Carrier
Keyword(s):  
Immune Thrombocytopenic Purpura ◽  
Immune Thrombocytopenia ◽  
Clinical Manifestations ◽  
High Dose ◽  
New Disease ◽  
First Line ◽  
Thrombocytopenic Purpura ◽  
High Dose Dexamethasone ◽  
Life Threatening ◽  
Hematological Manifestations

Abstract Purpose: COVID-19 is a new disease with many undescribed clinical manifestations. Material and methods: We report herein a case of severe immune thrombocytopenic purpura (ITP) in a critical COVID-19 patient.Results: A patient presented a severe episode of immune thrombocytopenia (< 10 x 109/L) 20 days after admission for a critical COVID-19. This thrombocytopenia was associated with a life-threatening bleeding. Response to first-line therapies was delayed as it took up to 13 days after initiation of intravenous immunoglobulin and high dose dexamethasone to observe an increase in platelet count. Conclusion: COVID-19 may be associated with late presenting severe ITP. Such ITP may also be relatively resistant to first-line agents. Hematological manifestations of COVID-19, such as the ones associated with life-threatening bleeding, must be recognized.

Surgical Control of Bleeding From Ovarian Torsion in the Setting of Immune Thrombocytopenic Purpura Without Splenectomy

2021 ◽  
pp. 000313482110111
Author(s):  
Taylor B. Shaw ◽  
Brenda Ma ◽  
Mark Barazza ◽  
David Sawaya
Keyword(s):  
Immune Thrombocytopenic Purpura ◽  
Pediatric Population ◽  
Bleeding Complications ◽  
Severe Bleeding ◽  
Platelet Destruction ◽  
Thrombocytopenic Purpura ◽  
Autoimmune Antibodies ◽  
Common Causes ◽  
Membrane Antigens ◽  
Acute Itp

Immune thrombocytopenic purpura (ITP) is a disorder caused by autoimmune antibodies which target glycoprotein IIb/IIIa complex or other platelet membrane antigens leading to platelet destruction. These platelets are then cleared by the spleen resulting in thrombocytopenia. Immune thrombocytopenic purpura affects about 1 to 6.4 cases in 100 000 children making it one of the most common causes of symptomatic thrombocytopenia in the pediatric population. It is rare that children or adolescents present with serious bleeding due to ITP. Common presentations include petechiae, bleeding gums, or bruising. Bleeding requiring hospitalization or transfusions is unusual and only occurs in approximately 5% of children. Even more uncommon is the presentation of severe bleeding complications requiring surgery for resolution. We present a case of a 17-year-old girl with acute ITP complicated by intraperitoneal hemorrhage and refractory thrombocytopenia due to ovarian cyst requiring oophorectomy.

Single Dose of Anti-CD20 Monoclonal Antibody (Rituximab) Treatment in Adults with Refractory Immune Thrombocytopenic Purpura (ITP).

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1077-1077
Author(s):  
Eri Tanaka ◽  
Shuji Hayashi ◽  
Katsumichi Fujimaki ◽  
Hiroyuki Fujita
Keyword(s):  
Platelet Count ◽  
Single Dose ◽  
Gastrointestinal Bleeding ◽  
Immune Thrombocytopenic Purpura ◽  
Intravenous Immunoglobulins ◽  
Thrombocytopenic Purpura ◽  
Platelet Counts ◽  
History Of ◽  
Refractory Itp

Abstract Refractory Immune Thrombocytopenic Purpura (ITP) is a difficult disease to treat effectively and the mortality approaches nearly 10% over 10 years. Moreover, the side effect profile of chronic steroid administration is undesirable due to the multi-systemic actions of these drugs. Recently, it has been reported in the literature that Rituximab is effective treatment for chronic ITP and it has been used at a dose of 375mg/m2 weekly for up to four weeks, as with lymphoma therapy. Rituximab is an expensive treatment, but according to previous data, patients treated with this drug have responded with increased and sustained platelet counts following only one infusion. Based on this, we treated five refractory ITP patients with single-dose Rituximab and all responded well. Patient 1 is with a 15 year history of ITP and Patient 2 is with a 34 year long history of ITP. Following treatment with Rituximab, although there was an interval of up to 7 months, both eventually responded well. Patient 3 is a 93 year old male who presented to our hospital with an acute presentation of ITP which involved severe gastrointestinal bleeding and this proved to be refractory to both steroids and intravenous immunoglobulins, but responded very quickly to Rituximab within 24 days. Patient 4 is a 75 year old female with diabetes mellitus and three-vessel coronary artery disease who presented with a bleeding diathesis. She was treated with steroids, intravenous immunoglobulins, danazol and azathioprine but with no response. Single-dose Rituximab was effective within 20 days with an improvement in platelet counts. Patient 5 is a 51 year old male with a six year history of ITP who presented to our hospital with massive intraabdominal and gastrointestinal bleeding and after Rituximab therapy his platelet count responded appropriately after 45 days. These patient responses were not associated with prior response to therapy, age, previous splenectomy, duration of ITP or platelet count. All patients tolerated treatment well except one patient who developed SLE-nephrotic syndrome 15 months later although it cannot be proven that such therapy induced this collagen-vascular diseases because Rituximab can be used to actually treat such conditions. Three patients remained in remission for more than one year after just one dose of the Rituximab therapy. Even from our small number of refractory ITP patients treated with Rituximab, it is our experience that single-dose treatment is also effective in some cases of refractory ITP and its effect may continue to provide long-term remission whereby it is now possible to decrease and even stop long-term steroid treatment in such patients.

scholarly journals Immune Thrombocytopenic Purpura (ITP) in Hepatitis B-Virus Infection - A Case Report

1970 ◽  
Vol 19 (1) ◽  
pp. 72-73 ◽  
Author(s):  
MK Uddin ◽  
MM Uddin ◽  
KA Gias Uddin ◽  
MH Sardar ◽  
MZ Hossain ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Immune Thrombocytopenic Purpura ◽  
Immune Thrombocytopenia ◽  
Hepatitis B Virus Infection ◽  
Thrombocytopenic Purpura ◽  
Petechial Haemorrhage ◽  
B Virus ◽  
Purpuric Rash

A 30 years old male presented with fever, headache, myalgia, anorexia, petechial haemorrhage, easy bruising, gum bleeding and purpuric rash. Initially it appeared to be a case of autoimmune thrombocytopenic purpura (ITP) but finally our patient was diagnosed as a case of immune thrombocytopenia due to hepatitis B-virus infection. In this report we document the immune thrombocytopenic purpura (ITP) in a 30 years old male patient which is due to hepatitis B-virus infection in the replicative phase. Assessment of the replicative status and activity of liver disease of the patient was done. Key words: Immune Thrombocytopenic Purpura (ITP); Hepatitis B-Virus Infection. DOI: 10.3329/jdmc.v19i1.6259 J Dhaka Med. Coll. 2010; 19(1) : 72-73.

Catastrophic anti-phospholipid syndrome with Libman-Sacks endocarditis following eltrombopag therapy for immune thrombocytopenic purpura: A case report

Lupus ◽  
2021 ◽  
pp. 096120332110651
Author(s):  
Sara Dichtwald ◽  
Avraham Meyer ◽  
Nisim Ifrach
Keyword(s):  
Case Report ◽  
Adverse Events ◽  
Lupus Erythematosus ◽  
Immune Thrombocytopenic Purpura ◽  
Intravenous Immunoglobulins ◽  
Young Female ◽  
The European Union ◽  
Positive Serology ◽  
Thrombocytopenic Purpura ◽  
Refractory Itp

Background Immune thrombocytopenic purpura (ITP) is an autoimmune disease, with accelerated destruction of platelets, estimated to affect 1.6–3.9 in 100,000 adults every year in the European Union. Glucocorticoids and intravenous immunoglobulins are common drug therapies. In refractory cases, drugs that enhance thrombopoiesis may be used. Eltrombopag is a thrombopoietin receptor agonist, known to increase platelet count in patients with refractory ITP. Thrombotic adverse events have been described in association with Eltrombopag administration. Case report A young female patient of Ethiopian ancestry with systemic lupus erythematosus, triple Antiphospholipid (APLA) positive serology and refractory ITP who received Eltrombopag and 2 weeks later developed catastrophic APLA syndrome with severe Libman-Sacks endocarditis of the mitral and aortic valves, multiple intracerebral infracts and arterial thrombosis of the left upper limb. Conclusion Eltrombopag is a salvage drug, used in refractory ITP. Thrombotic adverse events, some of which may be life-threatening, are a possible complication, especially in high-risk patients.

Sign in / Sign up

Export Citation Format

Share Document